Jenny

Ready in 24 Hours: ATreg Featured in Labiotech's GvHD Pipeline Review! The GvHD field is shifting from treating established disease toward preventing it by [...]

We are strengthening the IP foundation of our Treg platform! ActiTrexx GmbH is pleased to announce the publication of two new international patent applications [...]

First Clinical Trial on Activated Regulatory T Cells: Promising Breakthrough in Preventing the Dreaded Transplant Complication A team from University Medical Center Mainz and [...]

Publication Milestone: Actileucel First-in-Human Results Published in Transplantation and Cellular Therapy We're excited to share that our manuscript on Actileucel has been published in Transplantation [...]

Biotechfirma aus Mainz entwickelt Zelltherapie bei Blutkrebs Das kleine Biotech-Unternehmen ActiTrexx aus Mainz steht vor dem Durchbruch. Eine weltweit einzigartige Zelltherapie zur Behandlung bei [...]

ActiTrexx completes treatment of last patient with novel regulatory T cell therapy against Graft-versus-Host Disease Phase Ib/II study with Actileucel, a novel cellular product [...]

Interview with Aurelius Lie from SpacewalkTalks 2025 | Video On April 3rd, 2025, ActiTrexx had the great opportunity to speak with Aurelius Lie from [...]